|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12345678910111213...1819» |
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (clinicaltrials.gov) - Mar 3, 2017
P3, N=177, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed
- ||| Trial completion: Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=899, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Cosentyx (secukinumab) / Novartis
Trial completion: AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis (clinicaltrials.gov) - Mar 1, 2017
P2, N=276, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: GESTURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (clinicaltrials.gov) - Mar 1, 2017
P3, N=205, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Stelara (ustekinumab) / J&J
Phase classification, Reimbursement, Enrollment change, Claims database: Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database (clinicaltrials.gov) - Feb 13, 2017
P=N/A, N=2000, Active, not recruiting, Sponsor: Janssen Biotech, Inc.
Active, not recruiting --> Completed Phase classification: P4 --> P=N/A | N=1000 --> 2000
- fletikumab (NNC109-0012) / Novo Nordisk
Phase classification: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects (clinicaltrials.gov) - Feb 11, 2017
P1, N=55, Terminated, Sponsor: Novo Nordisk A/S
Phase classification: P4 --> P=N/A | N=1000 --> 2000 Phase classification: P1/2 --> P1
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment change: SIGNATURE: Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (clinicaltrials.gov) - Feb 11, 2017
P3, N=230, Completed, Sponsor: Novartis Pharmaceuticals
Phase classification: P1/2 --> P1 N=288 --> 230
- Trial completion: A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis (clinicaltrials.gov) - Feb 6, 2017
P2, N=24, Completed, Sponsor: China Medical University Hospital
N=288 --> 230 Recruiting --> Completed
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (clinicaltrials.gov) - Jan 31, 2017
P3, N=182, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Jan 18, 2017
P3, N=50, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || calcipotriol/betamethasone dipropionate / Generic mfg.
Trial primary completion date: An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects (clinicaltrials.gov) - Dec 13, 2016
P2, N=100, Recruiting, Sponsor: LEO Pharma
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Jun 2017
- tacrolimus topical / Generic mfg.
Trial primary completion date: Tacrolimus Ointment Interest (PROTOPIC (clinicaltrials.gov) - Dec 7, 2016
P3, N=240, Recruiting, Sponsor: University Hospital, Rouen
Trial primary completion date: Oct 2015 --> Jun 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: DERM: An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients (clinicaltrials.gov) - Dec 2, 2016
P=N/A, N=56, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- |||| Trial completion: Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Dec 1, 2016
P2, N=92, Completed, Sponsor: AmDerma
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Nov 30, 2016
P=N/A, N=140, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change, Trial withdrawal, Patient reported outcomes: Post Marketing Observational Study on Venezuelan Patients With Psoriasis (clinicaltrials.gov) - Nov 29, 2016
P=N/A, N=0, Withdrawn, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=10 --> 0 | Terminated --> Withdrawn
- | Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Phase classification: A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Nov 7, 2016
P3b/4, N=189, Completed, Sponsor: Merck KGaA
N=10 --> 0 | Terminated --> Withdrawn Phase classification: P4 --> P3b/4
- Januvia (sitagliptin) / Merck (MSD)
Enrollment closed: Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) (clinicaltrials.gov) - Oct 25, 2016
P2, N=118, Active, not recruiting, Sponsor: University College Dublin
Phase classification: P4 --> P3b/4 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Premature Coronary Artery Disease (CAD) in Severe Psoriasis (clinicaltrials.gov) - Oct 19, 2016
P1, N=46, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=120 --> 46
- Impoyz (clobetasol) / Encore
Trial primary completion date: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Sep 27, 2016
P2, N=50, Completed, Sponsor: Promius Pharma, LLC
Active, not recruiting --> Completed | N=120 --> 46 Trial primary completion date: Aug 2015 --> Apr 2016
- ||||| Cosentyx (secukinumab) / Novartis
Trial initiation date: SIGNATURE: Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (clinicaltrials.gov) - Sep 23, 2016
P3, N=288, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2015 --> Apr 2016 Initiation date: Oct 2012 --> Oct 2013
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: SIGNATURE: Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (clinicaltrials.gov) - Sep 22, 2016
P3, N=288, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2012 --> Oct 2013 Recruiting --> Completed
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: CLEAR: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis (clinicaltrials.gov) - Sep 22, 2016
P3, N=676, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis (clinicaltrials.gov) - Sep 9, 2016
P=N/A, N=126, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| tazarotene topical / Generic mfg.
Trial completion: Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Sep 7, 2016
P3, N=866, Completed, Sponsor: G & W Laboratories Inc.
Recruiting --> Completed Recruiting --> Completed
- ||||||| Hyrimoz (adalimumab-adaz) / Sandoz
Trial completion: ADACCESS: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (clinicaltrials.gov) - Sep 2, 2016
P3, N=465, Completed, Sponsor: Sandoz
Recruiting --> Completed Active, not recruiting --> Completed
- dimethyl fumarate controlled release (FP 187) / Forward Pharma
Enrollment change, Trial withdrawal, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 10, 2016
P3, N=0, Withdrawn, Sponsor: Forward-Pharma GmbH
Active, not recruiting --> Completed N=500 --> 0 | Not yet recruiting --> Withdrawn
- |||| Cosentyx (secukinumab) / Novartis
Trial primary completion date: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (clinicaltrials.gov) - Aug 9, 2016
P3, N=182, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=500 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Mar 2017 --> Oct 2016
- || Cosentyx (secukinumab) / Novartis
Trial primary completion date: AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis (clinicaltrials.gov) - Aug 9, 2016
P2, N=276, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2017 --> Oct 2016 Trial primary completion date: May 2017 --> Nov 2016
- || Cosentyx (secukinumab) / Novartis
Trial completion, Trial primary completion date: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - Aug 4, 2016
P3, N=12, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2017 --> Nov 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016
- | Impoyz (clobetasol) / Encore
Trial completion: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 4, 2016
P2, N=50, Completed, Sponsor: Promius Pharma, LLC
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016 Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Oct 2017
- |||| namilumab (IZN-101) / Amgen, Izana Biosci
Clinical: Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis (clinicaltrials.gov) - Jul 24, 2016
P2, N=120, Completed, Sponsor: Takeda
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Oct 2017 Recruiting --> Completed
- |||| remtolumab (ABT-122) / AbbVie
Trial completion, P2 data: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Jul 14, 2016
P2, N=231, Completed, Sponsor: AbbVie
Recruiting --> Completed Active, not recruiting --> Completed
- |||| toreforant (JNJ-38518168) / J&J
Trial completion: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Jul 12, 2016
P2, N=62, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Completed
- | Enbrel (etanercept) / Pfizer, Amgen
Trial initiation date, Trial termination: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Jun 30, 2016
P4, N=64, Terminated, Sponsor: Amgen
Recruiting --> Completed Initiation date: Oct 2011 --> Feb 2012 | Completed --> Terminated; Business decision due to slow enrollment
- |||| Humira (adalimumab) / AbbVie
Trial completion: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Jun 29, 2016
P4, N=100, Completed, Sponsor: Innovaderm Research Inc.
Initiation date: Oct 2011 --> Feb 2012 | Completed --> Terminated; Business decision due to slow enrollment Active, not recruiting --> Completed
- ||||||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial completion, Trial primary completion date: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Jun 24, 2016
P3, N=876, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015
- Biomarker, Trial completion: Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (clinicaltrials.gov) - Jun 17, 2016
P=N/A, N=210, Completed, Sponsor: George Washington University
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015 Recruiting --> Completed
- Trial completion, Enrollment change: A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis (clinicaltrials.gov) - Jun 17, 2016
P=N/A, N=150, Completed, Sponsor: George Washington University
Recruiting --> Completed Recruiting --> Completed | N=370 --> 150
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - May 27, 2016
P=N/A, N=246, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed | N=370 --> 150 Active, not recruiting --> Completed
- Trial completion: Reduction of Pain Caused by Biologic Drugs in Psoriasis (clinicaltrials.gov) - May 14, 2016
P=N/A, N=124, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, Trial primary completion date: DERM: An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients (clinicaltrials.gov) - May 13, 2016
P=N/A, N=56, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Sep 2016
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - May 12, 2016
P=N/A, N=140, Recruiting, Sponsor: AbbVie
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Sep 2016 Trial primary completion date: Mar 2017 --> Sep 2017
- Trial completion, Enrollment change, Trial primary completion date: Comparative Analysis of Small and Large Plaque Psoriasis (clinicaltrials.gov) - May 6, 2016
P=N/A, N=13, Completed, Sponsor: Rockefeller University
Trial primary completion date: Mar 2017 --> Sep 2017 Recruiting --> Completed | N=43 --> 13 | Trial primary completion date: Oct 2016 --> Jun 2015
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - May 6, 2016
P3, N=217, Completed, Sponsor: AbbVie
Recruiting --> Completed | N=43 --> 13 | Trial primary completion date: Oct 2016 --> Jun 2015 Active, not recruiting --> Completed
- | Xeljanz (tofacitinib) / Pfizer
Clinical: A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Apr 27, 2016
P3, N=2925, Terminated, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Terminated
- Sorilux (calcipotriene foam) / Mayne Pharma
Trial primary completion date: Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis (clinicaltrials.gov) - Apr 25, 2016
P1, N=30, Recruiting, Sponsor: Stiefel, a GSK Company
Recruiting --> Terminated Trial primary completion date: Aug 2015 --> Mar 2017
- |||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial primary completion date: NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (clinicaltrials.gov) - Apr 22, 2016
P3, N=876, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2015 --> Mar 2017 Trial primary completion date: Aug 2016 --> May 2016
- |||| Enrollment open: Natural Gels for Treatment of Plaque Psoriasis (clinicaltrials.gov) - Apr 20, 2016
P1/2, N=52, Recruiting, Sponsor: Secret of Youth
Trial primary completion date: Aug 2016 --> May 2016 Not yet recruiting --> Recruiting